식도 스텐트 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the esophageal stents market size is expected to increase from USD 244.51 million in 2025 to USD 257.81 million in 2026 and reach USD 335.99 million by 2031, growing at a CAGR of 5.44% over 2026-2031.

This report is Segmented by Product Type (Self-Expanding Metal Stents, Self-Expanding Plastic Stents, and Biodegradable Stents), Material (Nitinol, Stainless Steel, and Plastic/Polymer), Application (Malignant, Benign, and Tracheoesophageal Fistulas), End User (Hospitals, Specialty Clinics, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Esophageal Stents Market Trends and Insights

Rising Incidence Of Esophageal Cancer And Malignant Dysphagia

Esophageal cancer remains the strongest volume driver in the esophageal stents market, with 511,054 new cases and 445,391 deaths recorded globally in 2022. Global annual cases are projected to rise to 922,638 by 2050, which supports a long runway for palliative intervention demand. China represented 43.8% of the worldwide incidence in 2022, with 224,012 new diagnoses, which creates a very large regional treatment base for dysphagia management. The same projection work showed large future increases in East Asia and high human development index countries, so the disease burden is broadening across both mature and developing systems. Malawi and Uganda already reported age-standardized incidence rates of 17.9 and 13.2 per 100,000, yet access to advanced endoscopic care in many African settings remains limited. As oncology access improves in underserved regions, the esophageal stents market should benefit from both newly treated patients and higher procedural throughput.

Expanding Use Of Minimally Invasive Endoscopic Therapy

The shift from open surgery toward endoscopic management is changing how the esophageal stents market is used in routine care. Endoscopic stent placement can allow oral intake within 1 to 2 days and can reduce hospitalization time compared with surgical alternatives.That treatment pattern fits well with payer and provider efforts to limit inpatient use and shorten recovery time. Smaller delivery systems are also making placement more feasible in tight spaces and less dependent on highly specialized operating environments. This is helping more outpatient endoscopy units consider procedures that were once concentrated in large hospitals. As training expectations become more consistent, the esophageal stents market benefits from a broader pool of endoscopists who can perform placements safely and efficiently.

Stent-Related Complications And Re-Intervention Risk

Complications still limit how far the esophageal stents market can expand in benign disease. A 2024 multicenter study reported migration rates of 22.8% for conventional fully covered self-expanding metal stents and 26.6% for segmented fully covered self-expanding metal stents. Those rates sit within a broader published range of 4% to 54%, which shows that current engineering approaches have not fully resolved the problem. A 2025 systematic review and meta-analysis of biodegradable stents found hyperplastic tissue reactions in 16.4% of patients, with high heterogeneity across studies. Anchoring tools, such as through-the-scope suturing, may improve stability, but they also add equipment needs and operator skill requirements. This keeps many complex cases concentrated in tertiary centers and slows wider adoption across community settings in the esophageal stents market.

Other drivers and restraints analyzed in the detailed report include:

1. Product Innovation In Covered, Anti-Migration, And Biodegradable Designs
2. Broader Adoption In Palliative Care Pathways
3. Limited Reimbursement And Budget Pressure In Price-Sensitive Markets

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Self-expanding metal stents accounted for 73.48% of the esophageal stents market size in 2025. Their lead reflects long clinical use in malignant dysphagia, broad physician familiarity, and the availability of covered, partially covered, and uncovered formats for different stricture types. The esophageal stents market continues to lean heavily on this category because product progress is coming through steady refinement rather than full technology replacement. Self-expanding plastic stents now occupy a narrower role because larger catheter profiles, higher migration risk, and greater handling complexity have reduced their appeal in malignant use.

Biodegradable stents are projected to grow at 5.89% CAGR from 2026 to 2031 in the esophageal stents industry. Their main advantage is that they can degrade within 3 to 4 months and avoid a retrieval endoscopy in selected benign stricture cases. That makes growth in the esophageal stents market more additive than disruptive, because some patients who avoided stenting may accept a biodegradable option. A 2024 review found that biodegradable stents had not shown clear statistical superiority over self-expanding metal or plastic stents in meta-analyses, yet sequential placement strategies are receiving more attention for extending dysphagia-free intervals.

Nitinol held 68.24% of material revenue in 2025 within the esophageal stents market. Its shape memory, superelastic behavior, and stable radial force make it the standard material for devices that must function through repeated esophageal motion. This has steadily reduced the role of stainless steel in modern esophageal stent design. Established suppliers also benefit because validated material sourcing and manufacturing experience matter in regulated implantable devices.

Plastic and polymer materials are projected to grow at 6.32% CAGR through 2031 in the esophageal stents market. Part of that rise comes from cost pressure in outpatient procurement, while another part comes from faster work on biodegradable platforms. Polydioxanone and PLLA are central to this shift because they support temporary scaffolds that do not need later removal in selected use cases. A 2025 Biomaterials study described a degradable biomimetic stent with hydrogel and a directional TGF-loaded nanofiber membrane for esophageal fistula treatment, which shows how polymer research is moving beyond passive lumen support.

Complete Report Scope:

• By Product Type
  • Self-Expanding Metal Stents (SEMS)
  • Self-Expanding Plastic Stents (SEPS)
  • Biodegradable Stents
• By Material
  • Nitinol
  • Stainless Steel
  • Plastic/Polymer
• By Application
  • Malignant
  • Benign
  • Tracheoesophageal Fistulas
• By End User
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 37.68% of the esophageal stents market size in 2025. The United States accounted for most of that base because accredited endoscopy capacity, therapeutic expertise, and established reimbursement pathways supported high procedure throughput. Canada and Mexico added smaller contributions, with growth tied to oncology protocol development in Canada and private hospital investment in Mexico. The esophageal stents market in North America is also an important launch region for advanced covered stents because large health systems can adopt refinements faster than many other regions.

Asia-Pacific is forecast to expand at 8.93% CAGR through 2031 and is the fastest-growing region in the esophageal stents market. China represented 43.8% of global esophageal cancer incidence in 2022, which gives the region a very deep underlying treatment pool. Expansion of endoscopy infrastructure in China is opening more procedural capacity in second-tier and third-tier cities, which should support future placement volumes. Japan and South Korea remain early adopters of specialized stent platforms, and strong endoscopic practice patterns support quicker uptake of new designs. India is still smaller, but it is gaining traction as private tertiary hospitals expand advanced gastroenterology services.

Europe holds a steady position in the esophageal stents market, with Germany, the United Kingdom, France, and Italy supported by strong procedural standards and aging patient pools. South America is growing more gradually because public budget limits continue to weigh on adoption, even though private hospitals are adopting more advanced endoscopy protocols. The Middle East is seeing selective investment in oncology infrastructure, especially in GCC systems that are building advanced care capacity. Sub-Saharan Africa has some of the highest disease incidence, including 17.9 cases per 100,000 in Malawi, but much of that need remains commercially underserved because endoscopy access and reimbursement are still limited.

1. Beckton Dickinson
2. Boston Scientific
3. Cook Group
4. ELLA-CS, s.r.o.
5. EndoVastec
6. H & R Medical LLC
7. Hanarostent (M.I. Tech brand)
8. Hunan Handlike Medical
9. Leufen Medical
10. M.I. Tech Co., Ltd.
11. Meril Life Science
12. Merit Medical Systems
13. Micro-Tech Endoscopy Co., Ltd.
14. S&G Biotech Inc.
15. Taewoong Medical

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Incidence of Esophageal Cancer and Malignant Dysphagia
  • 4.2.2 Expanding Use of Minimally Invasive Endoscopic Therapy
  • 4.2.3 Product Innovation in Covered, Anti-Migration, and Biodegradable Designs
  • 4.2.4 Broader Adoption in Palliative Care Pathways
  • 4.2.5 Reimbursement Pull for Therapeutic Endoscopy in Mature Markets
  • 4.2.6 Growing Procedure Shift to Ambulatory and High-Throughput Endoscopy Settings
• 4.3 Market Restraints
  • 4.3.1 Stent-Related Complications and Re-Intervention Risk
  • 4.3.2 Limited Reimbursement and Budget Pressure in Price-Sensitive Markets
  • 4.3.3 Clinical Preference for Surgery or Other Definitive Therapies in Select Cases
  • 4.3.4 Evidence Gaps for Benign and Off-Label Indications
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Type
  • 5.1.1 Self-Expanding Metal Stents (SEMS)
  • 5.1.2 Self-Expanding Plastic Stents (SEPS)
  • 5.1.3 Biodegradable Stents
• 5.2 By Material
  • 5.2.1 Nitinol
  • 5.2.2 Stainless Steel
  • 5.2.3 Plastic/Polymer
• 5.3 By Application
  • 5.3.1 Malignant
  • 5.3.2 Benign
  • 5.3.3 Tracheoesophageal Fistulas
• 5.4 By End User
  • 5.4.1 Hospitals
  • 5.4.2 Specialty Clinics
  • 5.4.3 Ambulatory Surgical Centers
  • 5.4.4 Others
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as Available, Strategic Information, Market Rank/Share for Key Companies, Products & Services, and Recent Developments)
  • 6.3.1 Becton, Dickinson and Company
  • 6.3.2 Boston Scientific Corporation
  • 6.3.3 Cook Medical
  • 6.3.4 ELLA-CS, s.r.o.
  • 6.3.5 EndoVastec
  • 6.3.6 H & R Medical LLC
  • 6.3.7 Hanarostent (M.I. Tech brand)
  • 6.3.8 Hunan Handlike Medical
  • 6.3.9 Leufen Medical
  • 6.3.10 M.I. Tech Co., Ltd.
  • 6.3.11 Meril Life Sciences Pvt. Ltd.
  • 6.3.12 Merit Medical Systems, Inc.
  • 6.3.13 Micro-Tech Endoscopy Co., Ltd.
  • 6.3.14 S&G Biotech Inc.
  • 6.3.15 Taewoong Medical Co., Ltd.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment